Trial Profile
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
- 07 Nov 2018 According to a Bausch Health Companies Inc. media release, the U.S. FDA gave final approval for BRYHALI Lotion on Nov. 6, 2018, indicated for the topical treatment of plaque psoriasis in adult patients. BRYHALI Lotion had initially received a tentative approval from the FDA due to the pending expiration of exclusivity for a related product.
- 07 Nov 2018 According to a Bausch Health Companies media release, Lawrence J. Green, M.D., (associate clinical professor of Dermatology at George Washington University School of Medicine in Washington, D.C) is the lead investigator of this trial.
- 08 Oct 2018 Results presented in the Bausch Health Companies media release.